Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

Also called NCT01490918

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 165 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01490918
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01490918. Randomized; triple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2020-08-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Acarbose
Intervention (Drug)
Placebo acarbose
Intervention (Drug)
placebo metformin
Lead sponsor
The Catholic University of Korea (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01490918
Content hash
ec5f1e18bea44e739579bf3c75a08c9285c0fcdcaa519fec5b8ebeef54e9054b